Insights

Strategic Partnerships Cellvie has secured collaboration and grant activities with CSEM and Innosuisse, indicating openness to co-development and external validation. This suggests opportunities for joint research programs, contract work, and regional partnerships in Europe to accelerate therapeutic mitochondria transplantation initiatives.

Funding Momentum With a $16M funding backdrop and recent key investments from Taiho Ventures and Kizoo Technology Capital, there is evident investor confidence. This signals capacity for expanded clinical programs and potential for investors to back early access manufacturing, CRO collaborations, or specialty supply chain partnerships.

European Expansion Headquarters relocation to Zurich and office expansion in Western Europe signal a focus on the European market. This creates sales opportunities for regional CROs, regulatory consultants, manufacturing partners, and hospital-system pilot programs across Europe.

Clinical Readiness Positioned as a leader in Therapeutic Mitochondria Transplantation with ongoing heart attack and solid organ transplantation focus, cellvie presents a pathway for hospital systems and biotech enablers to pilot mitochondria-based therapies, requiring services in translational research, GMP-grade materials, and regulatory strategy support.

Technology Ecosystem The tech stack and digital cultivation of partnerships indicate readiness for integration with labs and data platforms. Potential sales angles include providing analytics, assay development services, or software-enabled monitoring tools to support mitochondrial therapy R&D and quality control workflows.

Similar companies to cellvie

cellvie Tech Stack

cellvie uses 8 technology products and services including RT-qPCR, Font Awesome, Google Fonts API, and more. Explore cellvie's tech stack below.

  • RT-qPCR
    Analytics
  • Font Awesome
    Font Scripts
  • Google Fonts API
    Font Scripts
  • jQuery
    Javascript Libraries
  • PWA
    Miscellaneous
  • Bootstrap
    UI Frameworks
  • Google Search Console
    Web Analytics
  • Nginx
    Web Servers

Media & News

cellvie's Email Address Formats

cellvie uses at least 2 email formats:
cellvie Email FormatsExamplePercentage
FL@cellvie.bioJD@cellvie.bio
96%
LFirst@cellvie.bioDJohn@cellvie.bio
4%

Frequently Asked Questions

What is cellvie's official website and social media links?

Minus sign iconPlus sign icon
cellvie's official website is cellvie.bio and has social profiles on LinkedIn and Crunchbase.

How much revenue does cellvie generate?

Minus sign iconPlus sign icon
As of October 2026, cellvie's annual revenue is estimated to be <$1M.

What is cellvie's SIC code and NAICS code?

Minus sign iconPlus sign icon
cellvie's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does cellvie have currently?

Minus sign iconPlus sign icon
As of October 2026, cellvie has approximately 11 employees across 2 continents, including Europe and North America. Key team members include Chief Operations Officer: M. B., Founder & Ceo: A. S. and Business & Office Manager: F. Z. Explore cellvie's employee directory with LeadIQ.

What industry does cellvie belong to?

Minus sign iconPlus sign icon
cellvie operates in the Biotechnology Research industry.

What technology does cellvie use?

Minus sign iconPlus sign icon
cellvie's tech stack includes RT-qPCR, Font Awesome, Google Fonts API, jQuery, PWA, Bootstrap, Google Search Console and Nginx.

What is cellvie's email format?

Minus sign iconPlus sign icon
cellvie's email format typically follows the pattern of FL@cellvie.bio. Find more cellvie email formats with LeadIQ.

How much funding has cellvie raised to date?

Minus sign iconPlus sign icon
As of October 2026, cellvie has raised $16M in funding. The last funding round occurred on Sep 09, 2025 for $5M.

When was cellvie founded?

Minus sign iconPlus sign icon
cellvie was founded in 2018.
cellvie logo

cellvie

Biotechnology ResearchSwitzerland11-50 Employees

cellvie is a Swiss biotechnology company focused on Therapeutic Mitochondria Transplantation, an approach intended to augment or replace mitochondria within cells. The technology, developed by Dr. James McCully at Harvard Medical School, is being advanced from bench to bedside with an initial focus on heart attacks and solid organ transplantation. Based in Zürich, Switzerland, the company operates with a small team pursuing clinical translation of mitochondria-based therapies.

In November 2023, cellvie announced a partnership with CSEM to collaborate on advancing its mitochondria-based therapy platform. The collaboration aligns with the goal of expanding its European presence and advancing its research program.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $16M

    cellvie has raised a total of $16M of funding over 4 rounds. Their latest funding round was raised on Sep 09, 2025 in the amount of $5M as a Seed.

  • <$1M

    cellvie's revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.